platelet-derived growth factor

(redirected from Platelet derived growth factor)
Also found in: Dictionary, Medical, Wikipedia.

platelet-derived growth factor

[¦plāt·lət də‚rīvd ′grōth ‚fak·tər]
(cell and molecular biology)
A glycolytic protein released by platelets and other cells that stimulates growth of cells of mesenchymal origin, for example, bone cartilage, vascular tissue, and connective tissue.
Mentioned in ?
References in periodicals archive ?
showed that the application of Platelet Derived Growth Factors BB (PDGF-BB) in the medial collateral ligament of rats increased the ultimate load, energy absorbed to failure, and elongation values compared with a control group [7].
Expressions of the basic fibroblast growth factor and platelet derived growth factor [beta] were significantly lower in the intima of drug treated groups with respect to the control group (p<0.
Vascular endothelial growth factor-A and platelet derived growth factor play a central role in the pathogenesis of digital clubbing.
Platelet Derived Growth Factor (PDGF)--PDGF is a very powerful regulatory growth factor and a sentinel growth factor that begins nearly all wound healing.
University of California (Oakland, CA) has patented compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family.
The Canadian patent will contain 200 claims covering compositions and methods of using recombinant platelet derived growth factor (rhPDGF-BB) combined with various matrix materials having defined characteristics.
Growth factors stored in the [alpha]-granules of platelets include platelet derived growth factor, insulin-like growth factor, vascular endothelial growth factor, and transforming growth factor-[beta].
today announced an agreement to jointly develop an innovative antibody to Platelet Derived Growth Factor Receptor Beta (PDGFR-?
This patent will cover methods of treating impaired bone to facilitate strengthening and healing of bone using novel compositions of recombinant human platelet derived growth factor (rhPDGF-BB) combined with matrix materials having defined characteristics.
NASDAQ: BMTI) today announced that it has received orphan drug designation from the Food and Drug Administration (FDA) for its protein therapeutic, recombinant human platelet derived growth factor (rhPDGF-BB), to be used in conjunction with autograft and/or commercially available osteochondral allograft for the treatment of osteochondritis dissecans (OCD) of the knee, elbow or ankle.
The allowed claims cover compositions of platelet derived growth factor (PDGF) combined with matrix materials having defined characteristics, which cover the Company's novel recombinant protein-device combination product candidates, including Augment[TM] Bone Graft and Augment[TM] Injectable Bone Graft, as well as GEMESIS([TM]), which the Company previously sold to Luitpold Pharmaceuticals, Inc.

Full browser ?